Selecta Biosciences (SELB) – Hot FDA News
-
Selecta Biosciences (SELB) Reports Phase 3 DISSOLVE Program of SEL-212 Met Primary Endpoint
-
Selecta Biosciences (SELB) Phase 1/2 Clinical Trial of SEL-302 for the Treatment of Methylmalonic Acidemia Placed on Clinical Hold
-
-
-
Back to SELB Stock Lookup